BTAI — BIOXCEL THERAPEUTICS INC
Health Care
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying BTAI?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their BTAI position last quarter, 3 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 63/100 in a Contraction regime).
- +3 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin, Howard Marks)
- +3 tracked investors reported holding BTAI at their latest filing
- +Macro Health is 57/100 in a Contraction regime — historically acceptable for Health Caresource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.
About BIOXCEL THERAPEUTICS INC (BTAI)
BIOXCEL THERAPEUTICS INC (BTAI) appears in the most recent 13F filings of 3 tracked institutional investors. BIOXCEL THERAPEUTICS INC is classified in the Health Care sector. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $3M. Across recent filings, tracked investors recorded 5 new positions, 2 increased, 1 reduced, and 3 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in BTAI
How many top investors track BTAI
A small number of top investors own this.
BTAI Ownership Composition
How BIOXCEL THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant62.1%
- Value & Distressed37.9%
Tracked investors currently reporting BTAI
- Izzy EnglanderJun 30, 2026Millennium ManagementShares2.1MValue$3M% Portfolio0.00%
- Howard MarksJun 30, 2026Oaktree Capital ManagementShares1.4MValue$1.9M% Portfolio0.03%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares149.2KValue$210.4K% Portfolio0.00%
Recent activity
- Increased$78.6K(4.91%)Nov 14, 2024
- Reduced$39.2K(-18.48%)Feb 14, 2025
- Sold$0(-100.00%)May 15, 2025
- Sold$0(-100.00%)Feb 17, 2026
- $3MAug 14, 2026
- New$436.6KAug 13, 2025
- Unchanged$617.4K(0.00%)Nov 13, 2025
- Unchanged$385.9K(0.00%)Feb 17, 2026
- Unchanged$323.2K(0.00%)May 20, 2026
- Increased$1.9M(472.27%)Aug 14, 2026
- New$20.6KAug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- New$210.4KAug 14, 2026
- $127.3KMay 15, 2024
Frequently asked questions
- How many institutional investors hold BTAI?
- 3 tracked institutional investors disclosed a position in BTAI (BIOXCEL THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of BTAI?
- Izzy Englander, Millennium Management, holds the largest disclosed position in BTAI, valued at $3M.
- Did institutional ownership of BTAI increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 2 increased, 1 reduced, and 3 fully exited BTAI.
- What sector is BTAI in?
- BIOXCEL THERAPEUTICS INC is classified in the Health Care GICS sector.
- Where does this BTAI ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.